-transparent.png){kind=logo}
1. The nephrotoxicity of gentamicin is well known. However, little information is available regarding the combined effects of gentamicin plus co-trimoxazole (sulfamethoxazole-trimethoprim). Therefore, Wistar rats were treated daily with 100 mg/kg gentamicin or 100 mg/kg gentamicin plus 30 mg/kg trimethoprim-150 mg/kg sulfamethoxazole for 14 days. 2. Serum biochemical parameters were measured on days 0, 8 and 15, and histopathological examinations of kidneys were performed on day 15, one day following end of treatment. Gentamicin treated rats exhibited a 63% increase in blood urea nitrogen (BUN), a 124% increase in uric acid, and a 63% decrease in serum potassium levels on day 15. 3. The combination of gentamicin plus co-trimoxazole partially ameliorated these effects. With the three drug combination no change occurred in BUN, and only a 30% decrease occurred in serum potassium levels. 4. While serum creatinine levels significantly increased following gentamicin, the co-administration of co-trimoxazole resulted in a significant decrease (30%) in creatinine. Histopathological examinations of kidneys suggested a lower degree of nephrotoxicity in rats treated with gentamicin plus co-trimoxazole as compared to animals treated with gentamicin alone. 5. The results support the importance of monitoring serum biochemical parameters when treating with gentamicin or gentamicin plus co-trimoxazole.
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
March 1979,
Lancet (London, England),
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
May 1984,
Lancet (London, England),
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
January 1991,
Pathologie-biologie,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
December 1983,
Australian and New Zealand journal of medicine,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
October 1974,
British medical journal,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
February 1989,
Pharmacology & toxicology,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
February 1983,
Australian and New Zealand journal of medicine,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
September 1981,
Research communications in chemical pathology and pharmacology,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
January 1978,
Antimicrobial agents and chemotherapy,
F V Izzettin, and
B Ayça, and
F Uras, and
V Uysal, and
U Cevikbaş, and
T Yardimci, and
S J Stohs
May 1976,
Antimicrobial agents and chemotherapy,
